The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis

Autor: Huan Tian, Wei Zhang, Shi-hong Yang
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Oncology
Adult
Cancer Research
medicine.medical_specialty
Disease free survival
Article Subject
Receptor
ErbB-2
medicine.medical_treatment
Treatment outcome
Locally advanced
Breast Neoplasms
Kaplan-Meier Estimate
Disease-Free Survival
Pathology and Forensic Medicine
03 medical and health sciences
0302 clinical medicine
Breast cancer
Internal medicine
medicine
Humans
Neoadjuvant therapy
Survival analysis
RC254-282
Aged
Neoplasm Staging
Aged
80 and over
Chemotherapy
QH573-671
business.industry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Cell Biology
General Medicine
Middle Aged
medicine.disease
Survival Analysis
Neoadjuvant Therapy
030104 developmental biology
Treatment Outcome
030220 oncology & carcinogenesis
Multivariate Analysis
Clinical Study
Molecular Medicine
Neoplasm staging
Female
business
Cytology
Zdroj: Analytical Cellular Pathology, Vol 2017 (2017)
Analytical Cellular Pathology (Amsterdam)
ISSN: 2210-7185
2210-7177
Popis: To provide reference data, we retrospectively investigated the effects of neoadjuvant chemotherapy (NAC) on 119 patients with HER-2+locally advanced breast cancer, treated from November 2010 to July 2016, with respect to influencing factors and survival. They were divided into the pathological complete response (pCR;n=15; 12.6%) and non-pCR (n=104; 87.4%) groups. We usedΧ2and logistic tests to the analyze effect and influencing factors. Survival rate was analyzed by the Kaplan-Meier method and Log-rank test. We lost 12 patients (including 1 pCR patient) and followed 107 patients, of whom 31 (all in the non-pCR group) had local recurrences or distant metastasis. The two groups significantly differed in 3-year disease-free survival (pCR group: 100%; non-pCR group: 59.0%;P=0.039); pCR was significantly affected by histological grade, PR status, Ki67 index, primary tumor size, clinical staging, and number of trastuzumab cycles. The model was tested, and the difference was statistically significant (Χ2 = 31.938,P=0.032). Patients with HER-2+locally advanced breast cancer with pCR responses to NAC have improved prognoses. Patients without pCR have increased risk for relapse. The use of a combination of NAC, such as trastuzumab and chemotherapy, and more cycles should be considered to increase the likelihood of pCR.
Databáze: OpenAIRE
Externí odkaz: